[Form 4] Twist Bioscience Corporation Insider Trading Activity
Twist Bioscience Corp (TWST) reporting person Adam Laponis, Chief Financial Officer, filed a Form 4 disclosing a non-discretionary sale of 918 shares of common stock on 08/21/2025 at a reported price of $25.964 per share. The filing states these shares were sold to satisfy tax withholding obligations associated with the vesting of restricted stock units under the companys equity plans, described as a mandatory "sell to cover" and not a discretionary trade.
Following the transaction, the reporting person beneficially owns 102,917 shares, which includes shares purchased under the companys Employee Stock Purchase Plan as noted in the filing. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Laponis and contains explanatory notes clarifying the nature of the sale and the ESPP exemption.
Twist Bioscience Corp (TWST), tramite il reporting person Adam Laponis, Chief Financial Officer, ha depositato un Modulo 4 che segnala la vendita non discrezionale di 918 azioni di azioni ordinarie in data 21/08/2025 al prezzo dichiarato di $25.964 per azione. Il deposito precisa che queste azioni sono state vendute per soddisfare gli obblighi di ritenuta fiscale connessi al vesting di unit脿 azionarie vincolate previste dai piani azionari della societ脿, descrivendo l'operazione come una vendita obbligatoria "sell to cover" e non come una transazione discrezionale.
A seguito della transazione, il reporting person detiene beneficiariamente 102.917 azioni, comprensive delle azioni acquistate tramite l'Employee Stock Purchase Plan (ESPP) della societ脿, come indicato nel deposito. Il Modulo 4 猫 stato firmato per procura da un avvocato e contiene note esplicative che chiariscono la natura della vendita e l'esenzione relativa all'ESPP.
Twist Bioscience Corp (TWST), representada por el reporting person Adam Laponis, Chief Financial Officer, present贸 un Formulario 4 que revela una venta no discrecional de 918 acciones ordinarias el 21/08/2025 a un precio informado de $25.964 por acci贸n. El documento indica que estas acciones se vendieron para cubrir obligaciones de retenci贸n fiscal asociadas al vesting de unidades restringidas de acciones bajo los planes de capital de la compa帽铆a, descrito como una venta obligatoria "sell to cover" y no como una operaci贸n discrecional.
Tras la transacci贸n, la persona informante posee beneficiosamente 102.917 acciones, que incluyen acciones adquiridas mediante el Employee Stock Purchase Plan (ESPP) de la compa帽铆a, seg煤n consta en el formulario. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Laponis y contiene notas aclaratorias que explican la naturaleza de la venta y la exenci贸n del ESPP.
Twist Bioscience Corp (TWST)鞚� 氤搓碃鞛� Adam Laponis(斓滉碃鞛毂呾瀯鞛�)電� 2025雲� 08/21鞐� 氤错喌欤� 918欤�毳� 欤茧嫻 $25.964鞐� 牍勳灛霟夓爜(non-discretionary)鞙茧 毵る弰頃� 雮挫毄鞚� 瓿奠嫓頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 須岇偓鞚� 歆�攵� 瓿勴殟 頃橃棎靹� 鞝滍暅欤检嫕 雼渼(RSU)鞚� 氩犾姢韺呾棎 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 毵る弰霅� 瓴冹溂搿�, 鞛焿鞝� 瓯半灅臧� 鞎勲媽 鞚橂鞝� "sell to cover" 瓯半灅搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟.
瓯半灅 頉� 氤搓碃鞛愲姅 Employee Stock Purchase Plan(ESPP)鞙茧 毵れ垬頃� 欤检嫕鞚� 韽暔頃橃棳 齑� 102,917欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅╇媹雼�. Form 4電� Laponis 鞌ゼ 雽�鞁犿暣 雽�毽� 氤�順胳偓臧� 靹滊獏頄堨溂氅�, 毵る弰鞚� 靹标博瓿� ESPP 甏�霠� 氅挫牅鞐� 雽�頃� 靹る獏 雲疙姼毳� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Twist Bioscience Corp (TWST), la personne d茅clarante Adam Laponis, Chief Financial Officer, a d茅pos茅 un Formulaire 4 divulguant une vente non discr茅tionnaire de 918 actions ordinaires le 21/08/2025 au prix d茅clar茅 de 25,964 $ par action. Le d茅p么t pr茅cise que ces actions ont 茅t茅 vendues pour satisfaire des obligations de retenue d'imp么t li茅es au vesting d'unit茅s d'actions restreintes relevant des plans d'actions de la soci茅t茅, d茅crivant l'op茅ration comme une vente obligatoire 芦 sell to cover 禄 et non comme une transaction discr茅tionnaire.
Apr猫s la transaction, la personne d茅clarante d茅tient directement 102 917 actions, y compris des actions achet茅es dans le cadre de l'Employee Stock Purchase Plan (ESPP) de la soci茅t茅, comme indiqu茅 dans le d茅p么t. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de M. Laponis et contient des notes explicatives clarifiant la nature de la vente et l'exemption ESPP.
Twist Bioscience Corp (TWST) meldete die berichtende Person Adam Laponis, Chief Financial Officer, in einem Form 4 eine nicht diskretion盲re Ver盲u脽erung von 918 Aktien des Stammkapitals am 21.08.2025 zu einem angegebenen Preis von $25.964 je Aktie. Die Einreichung gibt an, dass diese Aktien verkauft wurden, um Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Units unter den Aktienpl盲nen des Unternehmens zu erf眉llen; es handelte sich um ein verpflichtendes "sell to cover" und nicht um einen diskretion盲ren Handel.
Nach der Transaktion besitzt die berichtende Person wirtschaftlich 102.917 Aktien, einschlie脽lich der im Rahmen des Employee Stock Purchase Plan (ESPP) erworbenen Aktien, wie in der Einreichung vermerkt. Das Form 4 wurde von einem Bevollm盲chtigten im Namen von Herrn Laponis unterzeichnet und enth盲lt erl盲uternde Hinweise zur Art des Verkaufs und zur ESPP-Ausnahme.
- None.
- None.
Insights
TL;DR: Routine, non-discretionary sell-to-cover of RSU taxes by the CFO; no indication of insider-driven market-timing.
The Form 4 discloses a standard post-vesting sell-to-cover of 918 shares at $25.964 per share to satisfy tax withholding obligations. The filing explicitly states the sale was mandated by the issuer's equity plan, which supports the affirmative defense under Rule 10b5-1 for planned transactions when applicable. The reporting person retains a substantial direct stake of 102,917 shares, and the filing notes ESPP-acquired shares that were exempt under Rule 16b-3 provisions. From a governance perspective, this is a routine compliance disclosure with no red flags such as unexplained discretionary trades or sudden large disposals.
TL;DR: Small, tax-related disposition by the CFO; immaterial to company capitalization or control.
The reported disposition of 918 shares represents a minor, administrative sale tied to RSU vesting rather than an expression of view on company prospects. At the reported price of $25.964, the transaction value is modest relative to the reported retained holding of 102,917 shares. The disclosure also confirms participation in the ESPP, with those purchases treated as exempt in the filing. This transaction should not materially affect investor valuation metrics or signal management-level liquidity pressure.
Twist Bioscience Corp (TWST), tramite il reporting person Adam Laponis, Chief Financial Officer, ha depositato un Modulo 4 che segnala la vendita non discrezionale di 918 azioni di azioni ordinarie in data 21/08/2025 al prezzo dichiarato di $25.964 per azione. Il deposito precisa che queste azioni sono state vendute per soddisfare gli obblighi di ritenuta fiscale connessi al vesting di unit脿 azionarie vincolate previste dai piani azionari della societ脿, descrivendo l'operazione come una vendita obbligatoria "sell to cover" e non come una transazione discrezionale.
A seguito della transazione, il reporting person detiene beneficiariamente 102.917 azioni, comprensive delle azioni acquistate tramite l'Employee Stock Purchase Plan (ESPP) della societ脿, come indicato nel deposito. Il Modulo 4 猫 stato firmato per procura da un avvocato e contiene note esplicative che chiariscono la natura della vendita e l'esenzione relativa all'ESPP.
Twist Bioscience Corp (TWST), representada por el reporting person Adam Laponis, Chief Financial Officer, present贸 un Formulario 4 que revela una venta no discrecional de 918 acciones ordinarias el 21/08/2025 a un precio informado de $25.964 por acci贸n. El documento indica que estas acciones se vendieron para cubrir obligaciones de retenci贸n fiscal asociadas al vesting de unidades restringidas de acciones bajo los planes de capital de la compa帽铆a, descrito como una venta obligatoria "sell to cover" y no como una operaci贸n discrecional.
Tras la transacci贸n, la persona informante posee beneficiosamente 102.917 acciones, que incluyen acciones adquiridas mediante el Employee Stock Purchase Plan (ESPP) de la compa帽铆a, seg煤n consta en el formulario. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Laponis y contiene notas aclaratorias que explican la naturaleza de la venta y la exenci贸n del ESPP.
Twist Bioscience Corp (TWST)鞚� 氤搓碃鞛� Adam Laponis(斓滉碃鞛毂呾瀯鞛�)電� 2025雲� 08/21鞐� 氤错喌欤� 918欤�毳� 欤茧嫻 $25.964鞐� 牍勳灛霟夓爜(non-discretionary)鞙茧 毵る弰頃� 雮挫毄鞚� 瓿奠嫓頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 須岇偓鞚� 歆�攵� 瓿勴殟 頃橃棎靹� 鞝滍暅欤检嫕 雼渼(RSU)鞚� 氩犾姢韺呾棎 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 毵る弰霅� 瓴冹溂搿�, 鞛焿鞝� 瓯半灅臧� 鞎勲媽 鞚橂鞝� "sell to cover" 瓯半灅搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟.
瓯半灅 頉� 氤搓碃鞛愲姅 Employee Stock Purchase Plan(ESPP)鞙茧 毵れ垬頃� 欤检嫕鞚� 韽暔頃橃棳 齑� 102,917欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅╇媹雼�. Form 4電� Laponis 鞌ゼ 雽�鞁犿暣 雽�毽� 氤�順胳偓臧� 靹滊獏頄堨溂氅�, 毵る弰鞚� 靹标博瓿� ESPP 甏�霠� 氅挫牅鞐� 雽�頃� 靹る獏 雲疙姼毳� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Twist Bioscience Corp (TWST), la personne d茅clarante Adam Laponis, Chief Financial Officer, a d茅pos茅 un Formulaire 4 divulguant une vente non discr茅tionnaire de 918 actions ordinaires le 21/08/2025 au prix d茅clar茅 de 25,964 $ par action. Le d茅p么t pr茅cise que ces actions ont 茅t茅 vendues pour satisfaire des obligations de retenue d'imp么t li茅es au vesting d'unit茅s d'actions restreintes relevant des plans d'actions de la soci茅t茅, d茅crivant l'op茅ration comme une vente obligatoire 芦 sell to cover 禄 et non comme une transaction discr茅tionnaire.
Apr猫s la transaction, la personne d茅clarante d茅tient directement 102 917 actions, y compris des actions achet茅es dans le cadre de l'Employee Stock Purchase Plan (ESPP) de la soci茅t茅, comme indiqu茅 dans le d茅p么t. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de M. Laponis et contient des notes explicatives clarifiant la nature de la vente et l'exemption ESPP.
Twist Bioscience Corp (TWST) meldete die berichtende Person Adam Laponis, Chief Financial Officer, in einem Form 4 eine nicht diskretion盲re Ver盲u脽erung von 918 Aktien des Stammkapitals am 21.08.2025 zu einem angegebenen Preis von $25.964 je Aktie. Die Einreichung gibt an, dass diese Aktien verkauft wurden, um Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Units unter den Aktienpl盲nen des Unternehmens zu erf眉llen; es handelte sich um ein verpflichtendes "sell to cover" und nicht um einen diskretion盲ren Handel.
Nach der Transaktion besitzt die berichtende Person wirtschaftlich 102.917 Aktien, einschlie脽lich der im Rahmen des Employee Stock Purchase Plan (ESPP) erworbenen Aktien, wie in der Einreichung vermerkt. Das Form 4 wurde von einem Bevollm盲chtigten im Namen von Herrn Laponis unterzeichnet und enth盲lt erl盲uternde Hinweise zur Art des Verkaufs und zur ESPP-Ausnahme.
FAQ
What did TWST CFO Adam Laponis disclose on the Form 4?
Was the sale by the insider discretionary or mandatory?
How many TWST shares does the reporting person own after the transaction?
Does the Form 4 note any Employee Stock Purchase Plan (ESPP) activity?
Who signed the Form 4 for Adam Laponis?
